Increasing evidence has shown that the variety of APRIL’s signaling responses is shaped by the combined activation of pathways such as PI3K, NF-κB, and MAP kinases exerting different effects on cancer cells, which have been described in Table 1. This evidence concerns the gene TNFSF13 and cancer.